Ken Griffin Aligos Therapeutics, Inc. Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.35 - $1.07 $2,910 - $8,898	-8,316 Reduced 2.91%	277,363 $97,000
Q1 2024 May 15, 2024	BUY	$0.64 - $1.13 $182,834 - $322,817	285,679 New	285,679 $279,000
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.36 $53,416 - $81,624	-60,018 Reduced 68.3%	27,859 $27,000
Q1 2023 May 15, 2023	BUY	$0.87 - $2.11 $1,391 - $3,373	1,599 Added 1.85%	87,877 $76,000
Q4 2022 Feb 14, 2023	BUY	$0.89 - $28.0 $11,554 - $363,524	12,983 Added 17.71%	86,278 $81,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $27.5 $90,782 - $2.36 Million	-85,644 Reduced 53.88%	73,295 $80,000

253K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.